John M. Burke, MD | Hematologist in ...

Dr. John M. Burke, MD

Claim this profile

Rocky Mountain Cancer Centers - Aurora

Studies Lymphoma
Studies Chronic Lymphocytic Leukemia
7 reported clinical trials
13 drugs studied

Area of expertise

1Lymphoma
John M. Burke, MD has run 5 trials for Lymphoma. Some of their research focus areas include:
CD30 negative
HTLV-1 positive
2Chronic Lymphocytic Leukemia
John M. Burke, MD has run 3 trials for Chronic Lymphocytic Leukemia.

Affiliated Hospitals

Image of trial facility.
Rocky Mountain Cancer Centers-Aurora
Image of trial facility.
Rocky Mountain Cancer Centers

Clinical Trials John M. Burke, MD is currently running

Image of trial facility.

Cema-cel

for B-Cell Lymphoma

This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide. Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.
Recruiting1 award Phase 25 criteria
Image of trial facility.

Pirtobrutinib

for Chronic Lymphocytic Leukemia

The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years.
Recruiting1 award Phase 26 criteria

More about John M. Burke, MD

Clinical Trial Related13 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments John M. Burke, MD has experience with
  • Brentuximab Vedotin
  • Doxorubicin
  • Nivolumab
  • Dacarbazine
  • Cyclophosphamide
  • Prednisone

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does John M. Burke, MD specialize in?
Is John M. Burke, MD currently recruiting for clinical trials?
Are there any treatments that John M. Burke, MD has studied deeply?
What is the best way to schedule an appointment with John M. Burke, MD?
What is the office address of John M. Burke, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security